Biotia Funding: How Much Did They Raise & Key Investors

How Much Did Biotia Raise?
Funding & Key Investors

Biotia has successfully secured a significant capital injection, bringing its cumulative financing to $10.6M. This latest infusion of $8M marks a pivotal moment in the company's trajectory, signaling strong market confidence in its proprietary genomic diagnostic platform. By leveraging advanced sequencing and machine learning, the firm continues to solidify its position as a critical player in the global health security landscape.

The recent strategic investment underscores the growing demand for high-precision diagnostic tools capable of identifying complex infectious pathogens. As the company transitions from its foundational research phase into a more robust commercial scaling operation, this capital will be instrumental in accelerating the deployment of its diagnostic suite across clinical and research environments.

What is Biotia?

Biotia

Business Services

Research & Development

Healthcare Services

Biotia operates at the intersection of genomics and artificial intelligence, providing sophisticated diagnostic solutions for infectious diseases. The company's core technology, including the BIOTIA-DX and BIOTIA-ID platforms, enables clinicians and researchers to perform rapid, sensitive identification of microorganisms. By integrating modern sequencing technology with proprietary AI algorithms, Biotia addresses critical gaps in traditional diagnostic workflows, particularly for urinary and joint infections. Their strategic collaborations with high-profile institutions like the Mayo Clinic and the Rockefeller Foundation validate their technical approach and enhance their ability to monitor and respond to emerging infectious disease threats on a global scale.

How much funding has Biotia raised?

Biotia has raised a total of $10.6M across 3 funding rounds:

2019

Angel/Seed

$2.4M

2021

Debt

$155K

2022

Series A

$8M

Angel/Seed (2019): $2.4M with participation from Hyperplane Venture Capital and Falcon III Ventures

Debt (2021): $155K led by PPP

Series A (2022): $8M, investors not publicly disclosed

Key Investors in Biotia

Hyperplane Venture Capital

A Boston-based venture firm specializing in early-stage investments in machine intelligence, sensor technology, and cloud computing solutions.

Falcon III Ventures

An investment firm focused on providing strategic capital to high-growth technology companies within the healthcare and biotech sectors.

PPP

Public-Private Partnership

What's next for Biotia?

With this major enterprise-level funding, Biotia is well-positioned to scale its operational footprint and expand its diagnostic product pipeline. The company is expected to prioritize the commercialization of its existing genomic tools while deepening its research into novel pathogen detection methods. Future growth will likely focus on increasing market penetration within hospital systems and clinical laboratories, where the need for rapid, data-driven infectious disease insights remains acute. By maintaining its focus on high-accuracy sequencing and AI-driven analytics, Biotia is poised to become an indispensable partner in modern clinical diagnostics and public health surveillance.

See full Biotia company page

See More Financial Insights